Download Turbu+ Belgium APK latest version Free for Android
| Version | 2.1.19 |
| Update | 5 years ago |
| Size | 20.44 MB (21,429,066 bytes) |
| Developer | AstraZeneca Pharmaceuticals |
| Category | Apps, Medical |
| Package Name | com.astrazeneca.TurbuplusBelgium |
| OS | 4.4 and up |
Turbu+ Belgium APPLICATION description
You are only able to participate in the Turbu+ programme if enrolled by your Healthcare Professional.
Turbu+ is a programme intended to assist people with asthma and/or COPD in recording and monitoring the actuations of prescribed inhaler usage. Users will interact with the programme through a mobile app. This mobile app receives, stores, and displays inhalation/usage events from remote sensors in the compatible Bluetooth-enabled monitoring (Turbu+) device attached to the user’s inhaler, to support them in adhering to their prescribed treatment regime. The app also provides users with pre-configured medication reminders and motivational messages encouraging adherence with their prescribed medication.
The Turbu+ programme is not intended to:
• Diagnose, determine, modify or adapt the healthcare professional's treatment decisions
• Monitor, in real time, the user's medication use
• Determine or change the user's medication or treatment plan or to recommend such changes
• Alter or analyse inhaler usage information, other than by formatting the data for display.
Turbu+ is a patient support programme which has been designed, developed & fully sponsored by AstraZeneca UK Ltd. AstraZeneca UK Ltd is the manufacturer of the Turbu+ app whose registered address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. United Kingdom.
The Turbu+ device has been designed and developed by Adherium Europe Ltd.
NS ID XL-0120-RD09/2017-WEB
Turbu+ is a programme intended to assist people with asthma and/or COPD in recording and monitoring the actuations of prescribed inhaler usage. Users will interact with the programme through a mobile app. This mobile app receives, stores, and displays inhalation/usage events from remote sensors in the compatible Bluetooth-enabled monitoring (Turbu+) device attached to the user’s inhaler, to support them in adhering to their prescribed treatment regime. The app also provides users with pre-configured medication reminders and motivational messages encouraging adherence with their prescribed medication.
The Turbu+ programme is not intended to:
• Diagnose, determine, modify or adapt the healthcare professional's treatment decisions
• Monitor, in real time, the user's medication use
• Determine or change the user's medication or treatment plan or to recommend such changes
• Alter or analyse inhaler usage information, other than by formatting the data for display.
Turbu+ is a patient support programme which has been designed, developed & fully sponsored by AstraZeneca UK Ltd. AstraZeneca UK Ltd is the manufacturer of the Turbu+ app whose registered address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. United Kingdom.
The Turbu+ device has been designed and developed by Adherium Europe Ltd.
NS ID XL-0120-RD09/2017-WEB
↓ Read more
Old versions
| Version | Size | Update |
|---|---|---|
| ⇢ 2.1.19 (1 variants) | ↓ 20.44 MB | ◴ 5 years ago |
| ⇢ 2.1.18 (1 variants) | ↓ 20.44 MB | ◴ 5 years ago |
